Viking Therapeutics Inc (VKTX · NASDAQ)
VKTX · MARKET VIEW
Market view · as of Sep 21, 2026
Price (last ~year)
Viking Therapeutics, a clinical-stage biotech with no revenue, advanced its lead obesity candidate VK2735 into Phase 3 after roughly 15% weight loss in Phase 2, but the stock has fallen 23.4% over three months to $28.99, leaving it 31.2% below its 52-week high. The company reported a Q2 net loss of $128.0M with operating cash burn of $125.2M against $125.8M in cash and minimal debt ($4.1M), and has missed consensus EPS estimates in three of the last four quarters. Analysts' average target of $92.39 implies substantial upside from current levels, though the stock trades near oversold territory (RSI 32) amid a shareholder litigation investigation and elevated volume at 1.4x its 20-day average.
Valuation
- Market cap
- $3.38B
- PEG
- -0.03
- P/B
- 8.28
- EV/EBITDA
- -71.64
- Beta
- 0.679
- Analyst target
- $92.39
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -88.8%
- ROA
- -51.9%
Price movement
- Last
- $28.99
- 1-month
- -15.6%
- 3-month
- -23.4%
- RSI (14)
- 32
- vs SMA200
- -12.9%
- 52-wk position
- 23.4% -31.2% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $0 | $-132.6M | $-128.0M | $-127.9M |
| 2026-03-31 | $0 | $-164.1M | $-158.3M | $-158.3M |
| 2025-12-31 | $0 | $-164.7M | $-157.7M | $-157.6M |
| 2025-09-30 | $0 | $-98.6M | $-90.8M | $-90.7M |
Recent news
- Bullish Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss · 2026-09-15
- Somewhat-Bearish Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors · 2026-09-10
- Somewhat-Bullish Viking Therapeutics options flow signals binary event bet ahead of VK2735 readout · 2026-09-09
- Bearish Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm · 2026-09-07
- Somewhat-Bearish Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run? · 2026-09-04
- Neutral 3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong · 2026-09-03
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)